Compare · ABSI vs MEDP
ABSI vs MEDP
Side-by-side comparison of Absci Corporation (ABSI) and Medpace Holdings Inc. (MEDP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABSI and MEDP operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $17.14B, about 10.4x ABSI ($1.65B).
- MEDP has been more active in the news (10 items in the past 4 weeks vs 6 for ABSI).
- MEDP has more recent analyst coverage (25 ratings vs 21 for ABSI).
- Company
- Absci Corporation
- Medpace Holdings Inc.
- Price
- -
- -
- Market cap
- $1.65B
- $17.14B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2016
- News (4w)
- 6
- 10
- Recent ratings
- 21
- 25
Absci Corporation
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest ABSI
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- SEC Form 10-Q filed by Absci Corporation
- Absci Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
- SEC Form 4 filed by CMO, Head of R&D Somaratne Ransi Mudalinayake
- SEC Form 3 filed by new insider Somaratne Ransi Mudalinayake
- As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
- Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
- Director Szela Mary T bought $148,866 worth of shares (12,900 units at $11.54), increasing direct ownership by 154% to 21,300 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
Latest MEDP
- President & CEO Troendle August J. sold $9,969,094 worth of shares (15,978 units at $623.93), decreasing direct ownership by 3% to 545,217 units (SEC Form 4)
- CFO & Treasurer Brady Kevin M. exercised 3,400 shares at a strike of $138.87 and sold $2,125,816 worth of shares (3,400 units at $625.24) (SEC Form 4)
- President & CEO Troendle August J. sold $26,281,390 worth of shares (42,783 units at $614.30), decreasing direct ownership by 7% to 561,195 units (SEC Form 4)
- Director Carley Brian T sold $3,043,150 worth of shares (5,000 units at $608.63), decreasing direct ownership by 15% to 27,825 units (SEC Form 4)
- Director Davenport Fred B Jr exercised 7,583 shares at a strike of $116.08 and sold $4,414,590 worth of shares (7,283 units at $606.15), increasing direct ownership by 9% to 3,798 units (SEC Form 4)
- SEC Form 144 filed by Medpace Holdings Inc.
- President & CEO Troendle August J. sold $7,111,969 worth of shares (11,824 units at $601.49), decreasing direct ownership by 2% to 603,978 units (SEC Form 4)
- Director Mccarthy Cornelius P. Iii sold $690,122 worth of shares (1,140 units at $605.37), decreasing direct ownership by 8% to 12,275 units (SEC Form 4)
- President & CEO Troendle August J. sold $13,984,854 worth of shares (23,144 units at $604.25), decreasing direct ownership by 4% to 615,802 units (SEC Form 4)
- Director Mccarthy Cornelius P. Iii exercised 3,858 shares at a strike of $84.36 and sold $465,131 worth of shares (795 units at $585.07), increasing direct ownership by 30% to 13,415 units (SEC Form 4)